Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3821882 | 0.84 | TDP1 (0.79) | TDP1ESR1ESR2NPC1RAB9A | |
| SCHEMBL24765208 | 0.84 | TDP1 (0.67) | TDP1NPC1RAB9A | |
| SCHEMBL16673090 | 0.83 | TDP1 (0.76) | TDP1ESR1ESR2NPC1RAB9A | |
| SCHEMBL6232820 | 0.83 | TDP1 (0.76) | TDP1ESR1ESR2NPC1RAB9A | |
| SCHEMBL839075 | 0.82 | TDP1 (0.75) | TDP1ESR1ESR2NPC1RAB9A | |
| SCHEMBL8356618 | 0.82 | TDP1 (0.64) | TDP1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL29049842 | 0.81 | LMNA (0.63) | TDP1ESR1NPC1RAB9AKMT2A | |
| SCHEMBL5547338 | 0.81 | TDP1 (0.62) | TDP1ESR1ESR2NPC1RAB9A | |
| SCHEMBL223441 | 0.80 | TDP1 (1.00) | TDP1ESR1ESR2KMT2ASLC6A2 | |
| SCHEMBL28714878 | 0.80 | TDP1 (0.70) | TDP1ESR1ESR2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292269-A1 | BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292269-A1 | BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC3, BIRC2 | TDP1 104/4885SIGMAR1 4189/4885ESR1 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.